Unicycive Therapeutics, Inc.
UNCY- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001766140
No open-market purchases or sales by Unicycive Therapeutics, Inc. insiders were filed in the last 90 days; 79 institutions reported holding it in 13F filings for Q2 2026, worth $54.6M in total; no superinvestor holds it.
13F holders, Q1 2024
Institutional positions in Unicycive Therapeutics, Inc. as of Mar 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 23
- +7 vs. Q4 2023
- Shares held
- 21.2M
- +8.22M (+63.1%) vs. Q4 2023
- Total value
- $31.6M
- +$20.3M (+179.3%) vs. Q4 2023
- New holders
- 7
- 8 more added
- Sold out
- 0
- 2 more reduced
Compare with Q4 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting UNCY on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 79 | $54.6M |
| Q1 2026 | 51 | $65.2M |
| Q4 2025 | 35 | $47.5M |
| Q3 2025 | 30 | $27.4M |
| Q2 2025 | 20 | $24.6M |
| Q1 2025 | 29 | $34.5M |
| Q4 2024 | 31 | $49.0M |
| Q3 2024 | 29 | $19.1M |
| Q2 2024 | 24 | $9.52M |
| Q1 2024 | 23 | $31.6M |
| Q4 2023 | 16 | $11.3M |
| Q3 2023 | 16 | $12.2M |
| Q2 2023 | 15 | $1.38M |
| Q1 2023 | 13 | $3.54M |
| Q4 2022 | 9 | $428.3K |
| Q3 2022 | 12 | $571.0K |
| Q2 2022 | 15 | $992.0K |
| Q1 2022 | 12 | $1.48M |
| Q4 2021 | 12 | $2.30M |
| Q3 2021 | 10 | $3.02M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2024
Shares, value and share of portfolio for each institution holding Unicycive Therapeutics, Inc.; share changes are against Q4 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| JPMorgan Chase & Co | 47 | $65 | 0.00% | +47 | New |
| Wells Fargo & Company | 196 | $270 | 0.00% | +3+1.6% | Added |
| UBS Group AG | 4,387 | $6.05K | 0.00% | +4,211+2,392.6% | Added |
| Tower Research Capital LLC (TRC) | 7,678 | $10.6K | 0.00% | +919+13.6% | Added |
| Integrated Wealth Concepts LLC | 10,000 | $13.8K | 0.00% | 00.0% | Unchanged |
| Tandem Capital Management Corp | 15,500 | $21.4K | 0.01% | 00.0% | Unchanged |
| Captrust Financial Advisors | 18,800 | $25.9K | 0.00% | 00.0% | Unchanged |
| Ground Swell Capital, LLC | 19,118 | $26.4K | 0.03% | +19,118 | New |
| Northern Trust Corp | 23,998 | $33.1K | 0.00% | +23,998 | New |
| Virtu Financial LLC | 26,082 | $36.0K | 0.00% | +26,082 | New |
| State Street Corp | 35,036 | $48.4K | 0.00% | 00.0% | Unchanged |
| Citadel Advisors LLC | 69,395 | $95.8K | 0.00% | +33,975+95.9% | Added |
| Renaissance Technologies LLC | 92,860 | $128.0K | 0.00% | +58,766+172.4% | Added |
| Goldman Sachs Group Inc | 93,339 | $128.8K | 0.00% | −50.0% | Reduced |
| Geode Capital Management, LLC | 253,193 | $349.4K | 0.00% | +84,061+49.7% | Added |
| Vanguard Group Inc | 339,860 | $469.0K | 0.00% | +224,803+195.4% | Added |
| Monashee Investment Management LLC | 1,000,000 | $1.38M | 0.16% | +1,000,000 | New |
| Rosalind Advisors, Inc. | 1,879,646 | $2.59M | 2.43% | +1,879,646 | New |
| Logos Global Management LP | 3,469,927 | $3.01M | 0.32% | +3,469,927 | New |
| Vivo Capital, LLC | 3,470,152 | $4.79M | 0.38% | 00.0% | Unchanged |
| Ra Capital Management, L.P. | 3,470,688 | $4.79M | 0.06% | 00.0% | Unchanged |
| BVF Inc | 3,611,601 | $4.98M | 0.14% | +1,493,462+70.5% | Added |
| Nantahala Capital Management, LLC | 3,335,586 | $8.64M | 0.85% | −102,595−3.0% | Reduced |